

July 15, 2011

Mebiopharm Listed on TOKYO AIM

TOKYO AIM Inc., (“TOKYO AIM”) today welcomed Mebiopharm Co., Ltd. (“Mebiopharm”), a Japanese biotechnology firm, specializing in new drug development for cancer treatment, to the TOKYO AIM market.

Tetsutaro Muraki, President & CEO of TOKYO AIM, said: “We are delighted to welcome Mebiopharm as the first listed company on TOKYO AIM. There are many companies in Japan that are highly regarded by overseas professional investors and TOKYO AIM has been seeking to serve as a bridge between them. The listing of Mebiopharm is a major milestone for TOKYO AIM to this end. We will continue to work closely with J-Nomads to attract more Japanese and international companies from various sectors and provide professional investors with new investment opportunities.”

- Ends -

About TOKYO AIM, Inc.:

TOKYO AIM, Inc. was jointly established 2009 by the Tokyo Stock Exchange Group, Inc. (51%) and the London Stock Exchange plc (49%). TOKYO AIM, the equity market for professional investors which it operates, was established following the revision of the Japanese Financial Instruments and Exchange Act in 2008, employing a new structural framework with greater flexibility. The new bond market for professional investors, TOKYO PRO-BOND Market is established alongside the TOKYO AIM stock market, which allows for flexible and timely bond issuances. TOKYO AIM Inc. provides new avenues for capital raising for companies in Japan and Asia and responds to various needs of professional investors through its equity and bond markets. Website: <http://www.tokyo-aim.com>

Contacts for further information:

Kreab Gavin Anderson

+81-3-5404-0640 (Daniela STAWINOVA; Masako OKURA; Ami TAKAGAWA)

【Listing Ceremony】

